354 related articles for article (PubMed ID: 17051504)
1. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.
Cahn P; Villacian J; Lazzarin A; Katlama C; Grinsztejn B; Arasteh K; López P; Clumeck N; Gerstoft J; Stavrianeas N; Moreno S; Antunes F; Neubacher D; Mayers D
Clin Infect Dis; 2006 Nov; 43(10):1347-56. PubMed ID: 17051504
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.
Gathe J; Cooper DA; Farthing C; Jayaweera D; Norris D; Pierone G; Steinhart CR; Trottier B; Walmsley SL; Workman C; Mukwaya G; Kohlbrenner V; Dohnanyi C; McCallister S; Mayers D;
Clin Infect Dis; 2006 Nov; 43(10):1337-46. PubMed ID: 17051503
[TBL] [Abstract][Full Text] [Related]
3. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
Hicks CB; Cahn P; Cooper DA; Walmsley SL; Katlama C; Clotet B; Lazzarin A; Johnson MA; Neubacher D; Mayers D; Valdez H;
Lancet; 2006 Aug; 368(9534):466-75. PubMed ID: 16890833
[TBL] [Abstract][Full Text] [Related]
4. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials.
Hill A; Moyle G
HIV Med; 2007 May; 8(4):259-64. PubMed ID: 17461854
[TBL] [Abstract][Full Text] [Related]
5. Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
Cooper DA; Cordery DV; Zajdenverg R; Ruxrungtham K; Arastéh K; Bergmann F; Neto JL; Scherer J; Chaves RL; Robinson P;
PLoS One; 2016; 11(1):e0144917. PubMed ID: 26730818
[TBL] [Abstract][Full Text] [Related]
6. Tipranavir: PNU 140690, tipranivir.
Drugs R D; 2006; 7(1):55-62. PubMed ID: 16620137
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase 2 study.
Markowitz M; Slater LN; Schwartz R; Kazanjian PH; Hathaway B; Wheeler D; Goldman M; Neubacher D; Mayers D; Valdez H; McCallister S
J Acquir Immune Defic Syndr; 2007 Aug; 45(4):401-10. PubMed ID: 17554217
[TBL] [Abstract][Full Text] [Related]
8. Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance.
Luna B; Townsend MU
Clin Ther; 2007 Nov; 29(11):2309-18. PubMed ID: 18158073
[TBL] [Abstract][Full Text] [Related]
9. Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults.
Carr A; Ritzhaupt A; Zhang W; Zajdenverg R; Workman C; Gatell JM; Cahn P; Chaves R
AIDS; 2008 Nov; 22(17):2313-21. PubMed ID: 18981770
[TBL] [Abstract][Full Text] [Related]
10. Tipranavir: a ritonavir-boosted protease inhibitor.
Croom KF; Keam SJ
Drugs; 2005; 65(12):1669-77; discussion 1678-9. PubMed ID: 16060700
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients.
Gathe JC; Pierone G; Piliero P; Arasteh K; Rubio R; Lalonde RG; Cooper D; Lazzarin A; Kohlbrenner VM; Dohnanyi C; Sabo J; Mayers D
AIDS Res Hum Retroviruses; 2007 Feb; 23(2):216-23. PubMed ID: 17263650
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51).
Walmsley SL; Katlama C; Lazzarin A; Arestéh K; Pierone G; Blick G; Johnson M; Meier U; MacGregor TR; Leith JG
J Acquir Immune Defic Syndr; 2008 Apr; 47(4):429-40. PubMed ID: 18176328
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States.
Simpson KN; Roberts G; Hicks CB; Finnern HW
HIV Clin Trials; 2008; 9(4):225-37. PubMed ID: 18753117
[TBL] [Abstract][Full Text] [Related]
14. Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens.
de Requena DG; Bonora S; Calcagno A; D'Avolio A; Siccardi M; Fontana S; Milia MG; Sciandra M; Garazzino S; Di Garbo A; Baietto L; Trentini L; Di Perri G
Antimicrob Agents Chemother; 2008 Mar; 52(3):1066-71. PubMed ID: 18160524
[TBL] [Abstract][Full Text] [Related]
15. Tipranavir in highly antiretroviral treatment-experienced patients: Results from a French prospective cohort.
Allavena C; Flandre P; Pugliese P; Valantin MA; Poizot-Martin I; Cabié A; Melliez H; Cuzin L; Duvivier C; Dellamonica P; Raffi F;
Scand J Infect Dis; 2012 Jan; 44(1):37-43. PubMed ID: 21851330
[TBL] [Abstract][Full Text] [Related]
16. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial.
Zolopa AR; Berger DS; Lampiris H; Zhong L; Chuck SL; Enejosa JV; Kearney BP; Cheng AK
J Infect Dis; 2010 Mar; 201(6):814-22. PubMed ID: 20146631
[TBL] [Abstract][Full Text] [Related]
17. Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients.
de Mendoza C; Morelló J; Garcia-Gascó P; Rodríguez-Novoa S; Soriano V
Expert Opin Pharmacother; 2007 Apr; 8(6):839-50. PubMed ID: 17425479
[TBL] [Abstract][Full Text] [Related]
18. Tipranavir: a protease inhibitor from a new class with distinct antiviral activity.
Yeni P
J Acquir Immune Defic Syndr; 2003 Sep; 34 Suppl 1():S91-4. PubMed ID: 14562864
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents.
Salazar JC; Cahn P; Yogev R; Negra MD; Castelli-Gattinara G; Fortuny C; Flynn PM; Giaquinto C; Ruan PK; Smith ME; Mikl J; Jelaska A;
AIDS; 2008 Sep; 22(14):1789-98. PubMed ID: 18753862
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.
Katlama C; Esposito R; Gatell JM; Goffard JC; Grinsztejn B; Pozniak A; Rockstroh J; Stoehr A; Vetter N; Yeni P; Parys W; Vangeneugden T;
AIDS; 2007 Feb; 21(4):395-402. PubMed ID: 17301557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]